Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%

Certolizumab pegol vs placebo

Serious adverse events · Patients with active Crohn's disease

Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.35 [0.93, 1.97]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.84 [0.4, 1.78]
Studies not reported
Low

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Serious adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
Peto OR 1.47 [1.13, 1.91]
9 studies · 3927 participants
High